ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2019
Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- How to alleviate the shortage: a scoping review of prevention and management of global drug shortages.BMC public health · 2026Article
- Strategic resource allocation: an agent-based model of ambidextrous strategies in the pharmaceutical industry.Cost effectiveness and resource allocation : C/E · 2026Article
- Rarely listed essential medicines in 158 national lists.Journal of pharmaceutical policy and practice · 2026Article
- Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model.Cost effectiveness and resource allocation : C/E · 2024Article
- How does external reference pricing work in developing countries: evidence from Iran.Frontiers in pharmacology · 2023Article
- Health system to response to economic sanctions: global evidence and lesson learned from Iran.Globalization and health · 2022Review
- Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector.Research in pharmaceutical sciences · 2022Article
- Transparency in public pharmaceutical sector: the key informants' perceptions from a developing country.BMC health services research · 2021Article
- What impact does medicines shortages have on patients? A qualitative study exploring patients' experience and views of healthcare professionals.BMC health services research · 2021Article
- Physical rehabilitation in Iran after international sanctions: explored findings from a qualitative study.Globalization and health · 2020Article
- An application of analytic network process model in supporting decision making to address pharmaceutical shortage.BMC health services research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the past decades, economic sanctions imposed on Iran for its nuclear program. The embargo made difficulty in foreign trade and led to lack of timely access to medicines. As the internationally-led sanctions caused to the shortage of medicine there, healthcare systems need to applied the new policies for maintaining health service quality especially in pharmaceutical sector.
objectivesThis paper is about policies applied in Iran health system during the crisis reached its peak in 2012 as a good experience for guarantying access to pharmaceutical products.
methodsThrough interviewing experts and managers in pharmaceutical regulatory system, the implemented policies in targeted historical period were extracted, then quantitative data were analyzed to show the impact of the policies on the access and affordability of medicines before and after their implementation in Iran food and drug administration (IFDA). This paper tries to show strategies employed by to tackle the crisis caused by sanctions and to offer practical policies to make medicines more accessible at the time of crisis.
resultsIn order to reduce the harmful effects of this crisis, IFDA proposed some changes at different levels ranging from organizational procedures to parliament legislations. The main achievements of IFDA were making drugs easily available are as follows, significantly reducing prices, decreasing the share of market regarding the imported medicines, facilitating the manufacture of domestic medicines, encouraging foreign investment in manufacturing drugs domestically, controlling the shortage of drugs, and finally giving financial support to all patients in general and to those patients who had problem paying for drugs in particular.
conclusionThese experiences which made the Iran pharmaceutical sector survive during the international sanctions, can be considered as a good example of resilience strategies in similar situations. Graphical abstract IFDA policies to improve access to pharmaceutical products in sanction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.